Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 3/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 0.79 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.68 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.68 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.68 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlormidazole SCHEMBL30402878 | 1.00 | GALR3 (1.00) | GALR3NR2F2RAB9ATNFNOD1 | |
| Chlormidazole SCHEMBL364033 | 0.98 | GALR3 (0.97) | GALR3NR2F2RAB9ATNFNOD1 | |
| SCHEMBL6833621 | 0.89 | TNF (0.81) | GALR3NR2F2RAB9ATNFALDH1A1 | |
| SCHEMBL231295 | 0.88 | TNF (1.00) | GALR3NR2F2RAB9ATNFALDH1A1 | |
| SCHEMBL8220572 | 0.86 | TNF (0.77) | GALR3NR2F2RAB9ATNFNOD1 | |
| SCHEMBL3974900 | 0.86 | TNF (0.77) | GALR3NR2F2RAB9ATNFNOD1 | |
| SCHEMBL8320197 | 0.86 | TNF (0.77) | GALR3NR2F2RAB9ATNFNOD1 | |
| SCHEMBL9260111 | 0.86 | TNF (0.77) | GALR3NR2F2RAB9ATNFALDH1A1 | |
| SCHEMBL12771519 | 0.86 | GALR3 (1.00) | GALR3NR2F2RAB9ATNFHDAC1 | |
| SCHEMBL3974904 | 0.86 | TNF (0.77) | GALR3NR2F2RAB9ATNFNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1861 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| US-20250017904-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-01-16 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| WO-2023001264-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | 上海宝济药业有限公司 | 2023-01-26 | — | — | WO | claimed |
| US-20220387390-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-12-08 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999020271-A1 | USE OF AZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS | JOHNSON & JOHNSON CONSUMER FRANCE (FR) | 1999-04-29 | — | — | WO | claimed |
| EP-0599188-B1 | Trans and CIS traumatic acid salts having cicatrizant activity associated to bacteriostatic, antiviral, antibiotic or antifungal activity | LIFEGROUP SPA (IT) | 1997-08-06 | — | — | EP | claimed |
| US-5567716-A | FOR THE THERAPEUTIC TREATMENT OF CUTANEOUS PATHOLOGIES | LIFEGROUP S.P.A. (IT) | 1996-10-22 | — | — | US | claimed |
| EP-0599188-A1 | Trans and CIS traumatic acid salts having cicatrizant activity associated to bacteriostatic, antiviral, antibiotic or antifungal activity | LIFEGROUP S.p.A. (IT) | 1994-06-01 | — | — | EP | claimed |
| EP-0247142-A4 | FILM-FORMING, PHARMACEUTICAL VEHICLES FOR APPLICATION OF MEDICAMENTS TO NAILS, PHARMACEUTICAL COMPOSITIONS BASED ON THOSE VEHICLES, AND METHODS OF USING SAME. | DERMATOLOGICAL PRODUCTS TEXAS (US) | 1988-09-07 | — | — | EP | claimed |
| EP-0247142-A1 | FILM-FORMING, PHARMACEUTICAL VEHICLES FOR APPLICATION OF MEDICAMENTS TO NAILS, PHARMACEUTICAL COMPOSITIONS BASED ON THOSE VEHICLES, AND METHODS OF USING SAME. | DERMATOLOGICAL PRODUCTS OF TEX (US) | 1987-12-02 | — | — | EP | claimed |
| WO-1987002580-A1 | FILM-FORMING, PHARMACEUTICAL VEHICLES FOR APPLICATION OF MEDICAMENTS TO NAILS, PHARMACEUTICAL COMPOSITIONS BASED ON THOSE VEHICLES, AND METHODS OF USING SAME | DERMATOLOGICAL PRODUCTS OF TEXAS (US) | 1987-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017904-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | CAT, PRKDC, REN | GALR3 3668/4885NR2F2 4831/4885RAB9A 3702/4885 |
| US-20220387390-A1 | ANTIMICROBIAL COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF ACTIVATED CREATININE AND AN IMIDAZOLE ANTIFUNGAL AGENT | CAT, PRKDC, REN | GALR3 3668/4885NR2F2 4831/4885RAB9A 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.